Engineering Camptothecin Prodrugs for Cancer Therapy: An Exposure-First Perspective

Abstract Camptothecin (CPT)-derived anticancer agents stabilize topoisomerase I (TOP1)−DNA cleavage complexes (TOP1ccs), but their therapeutic utility is constrained by lactone instability, variable pharmacokinetics, and systemic toxicity. This Perspective evaluates prodrug strategies according to their initiating activation mechanisms, distinguishing self-immolative chemistry as a payload-release module. Small-molecule prodrugs are emphasized, alongside peptide−drug conjugates, antibody−drug conjugates, polymeric prodrugs, and nanoprodrugs. We propose an exposure-first, “design backward, validate forward” framework in which intended tumor exposure to active lactone and TOP1cc formation guide the payload selection, attachment site, activation compartment, linker kinetics, and delivery platform. Translational evaluation should establish colocalization of intact prodrug and accessible activating stimulus, faithful release of the intended payload, and a favorable balance between tumor exposure and exposure in dose-limiting normal tissues. Additional platform complexity should yield measurable pharmacological benefits. This framework provides practical criteria for prioritizing CPT prodrugs with the potential to improve the therapeutic index.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-11-16
DOI
https://doi.org/10.1021/acs.jmedchem.6c02288
Primary Topic
Cancer therapeutics and mechanisms
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Engineering Camptothecin Prodrugs for Cancer Therapy: An Exposure-First Perspective

Zongjiang Yu, Hongfei Jiang, Ting Zhou, Henghui Zhao et al.
1 links
Journal of Medicinal Chemistry
Cancer therapeutics and mechanisms
article

Engineering Camptothecin Prodrugs for Cancer Therapy: An Exposure-First Perspective

Zongjiang Yu, Hongfei Jiang, Ting Zhou, Henghui Zhao, Yunyu Zhao
article en

Abstract

Abstract Camptothecin (CPT)-derived anticancer agents stabilize topoisomerase I (TOP1)−DNA cleavage complexes (TOP1ccs), but their therapeutic utility is constrained by lactone instability, variable pharmacokinetics, and systemic toxicity. This Perspective evaluates prodrug strategies according to their initiating activation mechanisms, distinguishing self-immolative chemistry as a payload-release module. Small-molecule prodrugs are emphasized, alongside peptide−drug conjugates, antibody−drug conjugates, polymeric prodrugs, and nanoprodrugs. We propose an exposure-first, “design backward, validate forward” framework in which intended tumor exposure to active lactone and TOP1cc formation guide the payload selection, attachment site, activation compartment, linker kinetics, and delivery platform. Translational evaluation should establish colocalization of intact prodrug and accessible activating stimulus, faithful release of the intended payload, and a favorable balance between tumor exposure and exposure in dose-limiting normal tissues. Additional platform complexity should yield measurable pharmacological benefits. This framework provides practical criteria for prioritizing CPT prodrugs with the potential to improve the therapeutic index.

Journal of Medicinal Chemistry
Guangxi University (CN), Chinese Academy of Sciences (CN), Shandong Normal University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Bagui Scholars Program of Guangxi Zhuang Autonomous Region
Good health and well-being
Cancer therapeutics and mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon